½ÃÀ庸°í¼­
»óǰÄÚµå
1599902

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå : °Ë»ç¹ýº°, Ç÷§Æûº°, ÃÖÁ¾»ç¿ëÀÚº°, ¿ëµµº°, ±¹°¡º° - ºÐ¼®°ú ¿¹Ãø(2023-2033³â)

Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Platform, End User, Application, and Country - Analysis and Forecast, 2023-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 6¾ï 5,920¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù.

ÀÌ ½ÃÀåÀº ¿¹Ãø ±â°£ÀÎ 2023-2033³â¿¡ 15.43%ÀÇ CAGR·Î È®´ëÇϸç, 2033³â¿¡´Â 27¾ï 6,730¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÁöÁöÀûÀÎ ÇコÄɾî Á¤Ã¥ÀÇ Ã¤ÅÃ, ½ºÅ©¸®´× °Ë»çÀÇ º¸Çè Àû¿ë ¹üÀ§ È®´ë, Áö¼ÓÀû ±â¼ú Áøº¸, Áö¿ª Àüü¿¡¼­ÀÇ ±âȸ È®´ë, ÀÓ»êºÎ ¹× ÀÇ·á Á¦°øÀÚ »çÀÌ¿¡¼­ ºñħ½ÀÀû °Ë»ç ¹æ¹ý¿¡ ´ëÇÑ ¼±È£µµÀÇ Áõ°¡°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀåÀ» ÃßÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2023-2033³â
2023³â Æò°¡ 6¾ï 5,920¸¸ ´Þ·¯
2033³â ¿¹Ãø 27¾ï 6,730¸¸ ´Þ·¯
CAGR 15.43%

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀåÀº ÀÌ Áö¿ª¿¡¼­ ÇコÄɾî ÁöÃâÀÇ Áõ°¡¿Í Á¤±³ÇÑ Ãâ»ýÀü ½ºÅ©¸®´× ±â¼ú¿¡ °üÇÑ Áö½ÄÀÇ Áõ°¡¿¡ ÀÇÇØ Å©°Ô È®´ëÇϰí ÀÖ½À´Ï´Ù. NIPT´Â ³ôÀº Á¤È®¼º, ¾ÈÀü¼º, ºñħ½À¼ºÀ¸·Î ÀÎÇØ ¸ðü Ç÷¾×À¸·ÎºÎÅÍ ¼¼Æ÷¸¦ Æ÷ÇÔÇÏÁö ¾ÊÀº žÆÀÇ DNA¸¦ Á¶»çÇϴ ȹ±âÀûÀÎ ±â¼ú·Î¼­ ´õ¿í ´õ ÀαⰡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÓ½ÅÁß ÆÄŸ¿ì ÁõÈıº, ¿¡µå¿öÁî ÁõÈıº, ´Ù¿î ÁõÈıº°ú °°Àº ¿°»öü ÀÌ»óÀ» È®ÀÎÇÏ´Â µ¥ ÀÚÁÖ »ç¿ëµË´Ï´Ù.

»ê¸ðÀÇ °í·ÉÈ­, ÷´Ü À¯ÀüÀÚ ±â¼úÀÇ È°¿ë, Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ »êÀü Áø´ÜÀÇ Çʿ伺ÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖÀ¸¸ç, NIPTÀÇ Ã¤ÅÃÀº ¸¹Àº ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡¿¡¼­ »êÀü Áø´Ü¿¡ ´ëÇÑ º¸Çè Àû¿ë È®´ë¿Í ÀÇ·á °³ÇõÀÇ ½ÃÇàÀ¸·Î ÀÎÇØ ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ÀÌ Áö¿ªÀÇ ´Ù¾çÇÑ Àα¸¿Í ´Ù¾çÇÑ ¼Òµæ ¼öÁØ¿¡ ´ëÀÀÇϱâ À§ÇØ ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ °Ë»ç ¼Ö·ç¼Ç °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­ ±¹Á¦ ±â¾÷°ú Áö¿ª ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿ÍÀÇ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ÀÎÁöµµ¿Í Á¢±Ù¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºñħ½ÀÀû Ãâ»ýÀü °Ë»ç(NIPT) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í °Ë»ç¹ýº°, Ç÷§Æûº°, ÃÖÁ¾»ç¿ëÀÚº°, ¿ëµµº°, ±¹°¡º° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ÀÇ °³¿ä µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

°³¿ä

Á¦1Àå ½ÃÀå

  • µ¿Çâ : ÇöÀç ¹× ÇâÈÄ ¿µÇâ Æò°¡
  • °ø±Þ¸ÁÀÇ °³¿ä
  • ¿¬±¸°³¹ß ¸®ºä
  • ±ÔÁ¦ »óȲ
  • »óȯ ½Ã³ª¸®¿À
  • ½ÃÀå ¿ªÇÐÀÇ °³¿ä

Á¦2Àå Áö¿ª

  • ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ
  • Áö¿ªº° °³¿ä
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦3Àå ½ÃÀå - °æÀï º¥Ä¡¸¶Å·°ú ±â¾÷ °³¿ä

  • °æÀï ±¸µµ
    • BGI Genomics
    • Annoroad Gene Technology

Á¦4Àå Á¶»ç ¹æ¹ý

KSA 24.12.11

Introduction to Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market

The Asia-Pacific NIPT market was valued at $659.2 million in 2023 and is expected to reach $2,767.3 million by 2033, registering a CAGR of 15.43% during the forecast period 2023-2033. The adoption of supportive healthcare policies, the growing inclusion of screening procedures in insurance coverage, ongoing technological advancements, the expansion of commercial opportunities throughout the region, and the growing preference for non-invasive testing methods among expectant parents and healthcare providers are the main factors propelling the APAC NIPT market.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$659.2 Million
2033 Forecast$2,767.3 Million
CAGR15.43%

The market for non-invasive prenatal testing (NIPT) in Asia-Pacific is expanding significantly due to increased healthcare spending in the region and growing knowledge of sophisticated prenatal screening techniques. Because of its great accuracy, safety, and non-invasiveness, NIPT-a ground-breaking technology that examines cell-free fetal DNA from maternal blood-is becoming more and more popular. During pregnancy, it is frequently used to identify chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome.

Growing maternal age, the use of sophisticated genetic technologies, and the need for accurate and timely prenatal diagnostics are driving the market's growth. The adoption of NIPT is being further supported by the expansion of insurance coverage for prenatal care and the implementation of healthcare reforms in many Asia-Pacific nations.

The market's major players are concentrating on creating affordable testing solutions to serve the region's diverse population and range of income levels. Partnerships between international corporations and regional healthcare providers are increasing awareness and accessibility, especially in developing nations.

As prenatal health awareness rises and healthcare infrastructure improves, the APAC NIPT market is expected to grow rapidly. It will be crucial in improving maternal and fetal health outcomes throughout the area.

Market Segmentation:

Segmentation 1: by Application

  • Trisomy Detection
  • Microdeletion Detection
  • Sex Chromosome Aneuploidy Detection
  • Others

Segmentation 2: by End User

  • Hospitals
  • Diagnostic Laboratories
  • Others

Segmentation 3: by Platform

  • NGS
  • PCR
  • Others

Segmentation 4: by Method

  • cfDNA
  • FCMB

Segmentation 5: by Country

  • China
  • India
  • Japan
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Workflow/Innovation Strategy: The Asia-Pacific NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.

Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.

Competitive Strategy: Key players in the Asia-Pacific NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Asia-Pacific NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

  • BGI Genomics
  • Annoroad Gene Technology

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
    • 1.1.2 Expanding Applications in NIPT Products
  • 1.2 Supply Chain Overview
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Regulatory Scenario in China
    • 1.4.2 Regulatory Scenario in India
    • 1.4.3 Regulatory Scenario in Australia
    • 1.4.4 Regulatory Scenario in Japan
  • 1.5 Reimbursement Scenario
  • 1.6 Market Dynamics Overview
    • 1.6.1 Market Drivers
      • 1.6.1.1 High Incidence of Genetic Disorders
      • 1.6.1.2 Rising Maternal Age
      • 1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
      • 1.6.1.4 Increased Emphasis on Early Detection and Prevention
    • 1.6.2 Market Restraints
      • 1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
      • 1.6.2.2 Lack of Awareness Regarding NIPT
      • 1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
    • 1.6.3 Market Opportunities
      • 1.6.3.1 Leveraging the Opportunities Arising from the Growing Markets in Asia
      • 1.6.3.2 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)

2 Regions

  • 2.1 Drivers and Restraints
  • 2.2 Regional Summary
  • 2.3 Asia-Pacific
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 China
    • 2.3.7 India
    • 2.3.8 Japan
    • 2.3.9 Rest-of-Asia-Pacific

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 BGI Genomics
      • 3.1.1.1 Overview
      • 3.1.1.2 Product Portfolio
      • 3.1.1.3 Top Competitors
      • 3.1.1.4 Target Customers
      • 3.1.1.5 Key Personnel
      • 3.1.1.6 Analyst View
    • 3.1.2 Annoroad Gene Technology
      • 3.1.2.1 Overview
      • 3.1.2.2 Product Portfolio
      • 3.1.2.3 Top Competitors
      • 3.1.2.4 Target Customers
      • 3.1.2.5 Key Personnel
      • 3.1.2.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦